Skip to main content

VRTX Vertex Pharmaceuticals Incorporated

Healthcare

553.15 -5.73 -1.03% Close 11/2
Since 2024-12-02 +20.0%
Open
560.88
High
568.67
Low
544.09
Prev close
558.88
Volume
3M
Amplitude
4.40%
P/E
32.5
P/B
7.0
Revenue YoY (TTM)
+10.6%
52W 403.16 568.67

Is Vertex Pharmaceuticals Incorporated a buy? Fundamentals and valuation first

As of 2026-10-30

Quality: Strong, Growth: Good, Momentum: Strong, Risk / liquidity: Strong; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but Price / book is Expensive.
TTM P/E 32.53 71th percentile Pricey
Price / book 7 88th percentile Expensive
Free-cash-flow yield (%) 2.68 57th percentile Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Strong All 3 indicators are Top.
ROE, TTM (%) 21.76 84th percentile Top
Operating margin, TTM (%) 38.59 88th percentile Top
FCF margin, TTM (%) 30.07 86th percentile Top
Quality Factor Investing: A US Quality Value Backtest
Growth Good All 2 indicators are Good.
Revenue growth, TTM YoY (%) 10.56 62th percentile Good
Diluted EPS growth, TTM YoY (%) 22.8 68th percentile Good
Momentum Strong 60-day return is Top; 240-day return is Good.
60-day return (%) 15.46 89th percentile Top
240-day return (%) 27.85 77th percentile Good
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Strong 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 706,227,472 98th percentile Top
60-day annualized volatility (%) 29.07 33th percentile Good
Factor Investing Explained: 10 Classic Factors in US Stocks

Vertex Pharmaceuticals Incorporated (VRTX) today

3 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Vertex Pharmaceuticals Incorporated to every stock like it

AI finds several complementary traits of Vertex Pharmaceuticals Incorporated across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated (VRTX) peers and tracking

Watchlist

This page refreshes daily after the close. Add Vertex Pharmaceuticals Incorporated to your watchlist to track signal changes on your next visit.

Vertex Pharmaceuticals Incorporated (VRTX) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

32 historical occurrences (since 2017-03-29)

Average forward return after 52-week adjusted-price high

20-day: Win 45.2%, Sample 31, Median -1.61%, Excess -0.45%, Beat mkt rate 38.7%

60-day: Win 56.7%, Sample 30, Median +2.58%, Excess +1.8%, Beat mkt rate 53.3%

120-day: Win 72.4%, Sample 29, Median +6.68%, Excess +0.95%, Beat mkt rate 48.3%

120 days after: historical avg +5.93%

20-day +0.22%
60-day +3%
120-day +5.93%
20-day
60-day
120-day
Win
45.2%
56.7%
72.4%
Sample
31
30
29
Median
-1.61%
+2.58%
+6.68%
Excess
-0.45%
+1.8%
+0.95%
Beat mkt rate
38.7%
53.3%
48.3%

Over 29 occurrences, 120-day forward avg gained 5.93%, beat the market by 0.95 pts; win rate 72.4%.

Top-quintile 6-month momentum

Active · now 84.89%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
18 historical occurrences (since 2017-03-31)

Average forward return after Top-quintile 6-month momentum

20-day: Win 58.8%, Sample 17, Median +2.14%, Excess +1.12%, Beat mkt rate 52.9%

60-day: Win 76.5%, Sample 17, Median +8.32%, Excess +4.74%, Beat mkt rate 58.8%

120-day: Win 76.5%, Sample 17, Median +7.82%, Excess +3.74%, Beat mkt rate 52.9%

120 days after: historical avg +10.75%

20-day +2.29%
60-day +7.99%
120-day +10.75%
20-day
60-day
120-day
Win
58.8%
76.5%
76.5%
Sample
17
17
17
Median
+2.14%
+8.32%
+7.82%
Excess
+1.12%
+4.74%
+3.74%
Beat mkt rate
52.9%
58.8%
52.9%

Over 17 occurrences, 120-day forward avg gained 10.75%, beat the market by 3.74 pts; win rate 76.5%.

Filed revenue acceleration

Active · now 10.56%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

16 historical occurrences (since 2018-07-26)

Average forward return after Filed revenue acceleration

20-day: Win 56.2%, Sample 16, Median +0.51%, Excess +3.67%, Beat mkt rate 62.5%

60-day: Win 68.8%, Sample 16, Median +8.79%, Excess +4.5%, Beat mkt rate 62.5%

120-day: Win 73.3%, Sample 15, Median +8.33%, Excess +0.57%, Beat mkt rate 66.7%

120 days after: historical avg +5.85%

20-day +3.22%
60-day +5.67%
120-day +5.85%
20-day
60-day
120-day
Win
56.2%
68.8%
73.3%
Sample
16
16
15
Median
+0.51%
+8.79%
+8.33%
Excess
+3.67%
+4.5%
+0.57%
Beat mkt rate
62.5%
62.5%
66.7%

Over 15 occurrences, 120-day forward avg gained 5.85%, beat the market by 0.57 pts; win rate 73.3%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 169+13.1% +13.6% 72.2% +2.9%
20-40 441+16.5% +20.9% 66.2% +1.7%
40-60 431+21.6% +21.4% 96.8% +0.6%
60-80 You are here107+5.1% +6.9% 68.2% -31.2%
80-100 0Insufficient data

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 32.53, placing it in the 69.5 own-history percentile, inside the 60-80 bucket.

More history: Valuation × momentum analogs, Market-wide momentum baseline, Signals not active now

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
-0.4%
Win rate 55.8% Excess -8.4%
104d
+7.5%
Win rate 73.4% Excess -1.3%
654d
Now
Insufficient data
(28d)
60-day momentum down
+0.5%
Win rate 41.5% Excess -10.6%
289d
+18.8%
Win rate 94.3% Excess +10.5%
193d
Insufficient data
(0d)

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

31 times historically; 60-day forward avg +7.27%, win rate 64.3%, beating the market by +4.03 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.